Claims
- 1. A method of treating or preventing a neurodegenerative disorder of the retina or optic nerve head in a patient suffering from or predisposed to such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:
- 2. The method of claim 1 wherein
R=H, C1-2 alkyl; Y=NR′R″; R′=H, C1-6 (un)branched alkyl, —(CH2)nZ(CH2)n′A; Z=nothing, O, CHOR3, NR3; R3 H; A=H, OH, (un)substituted aryl (substitution as defined by X below); X and X′ independently=H, F, Cl, Br, CN, CF3, OR′, SR4, R4; R″=H; R4=C1-4 (un)branched alkyl; m=0-2; m′=0-2; W=H; n=2-4; and n′=0-3.
- 3. The method of claim 2 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.
- 4. The method of claim 1 wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.
- 5. The method of claim 4 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).
- 6. The method of claim 1 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.
- 7. A method of treating or preventing a disorder of the retina or optic nerve head in a patient suffering from or predisposed to such a disorder which comprises administering to the patient a therapeutically effective amount of 3-benzoylphenylacetic acid or derivative of the formula:
- 8. The method of claim 7 wherein
R=H, C1-2 alkyl; Y=NR′R″; R′=H, C1-6 (un)branched alkyl, —(CH2)nZ(CH2)n′A; Z=nothing, O, CHOR3, NR3; R3=H; A=H, OH, (un)substituted aryl (substitution as defined by X below); X and X′ independently=H, F, Cl, Br, CN, CF3, OR′, SR4, R4; R″=H; R4=C1-4 (un)branched alkyl; m=0-2; m′=0-2; W=H; n=2-4; and n′=0-3.
- 9. The method of claim 8 wherein the 3-benzoylphenylacetic acid or derivative is selected from the group consisting of 2-Amino-3-(4-fluorobenzoyl)-phenylacetamide; 2-Amino-3-benzoyl-phenylacetamide; and 2-Amino-3-(4-chlorobenzoyl)-phenylacetamide.
- 10. The method of claim 7 wherein the 3-benzoylphenylacetic acid or derivative is topically administered to the eye.
- 11. The method of claim 10 wherein the therapeutically effective amount of 3-benzoylphenylacetic acid or derivative is from about 0.001 to about 4.0% (w/v).
- 12. The method of claim 7 wherein the 3-benzoylphenylacetic acid or derivative is administered orally, intravenously, in a subconjunctival injection or implant, in a sub-Tenon's injection or implant, in an intravitreal injection or implant, or in a surgical irrigating solution.
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application, Serial No. 60/225,132, filed Aug. 14, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60225132 |
Aug 2000 |
US |